Steer­ing clear of Fi­bro­Gen/As­traZeneca wreck­age, Glax­o­SmithK­line spot­lights piv­otal da­ta for star ane­mia drug

We now know ex­act­ly what Glax­o­SmithK­line will be tak­ing to the FDA and EMA as it pitch­es its oral ane­mia drug for pa­tients with chron­ic kid­ney dis­ease.

Hand­picked by Hal Bar­ron as one of the top late-stage drugs in the pipeline — and lin­ing up as the first big launch un­der Em­ma Walm­s­ley’s new GSK — dapro­du­s­tat be­longs to a class known as hy­pox­ia-in­ducible fac­tor pro­lyl hy­drox­y­lase (HIF-PH) in­hibitors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER